Protein Summary
Zinc metalloprotease that specifically cleaves 'Lys-63'-linked polyubiquitin chains. Does not cleave 'Lys-48'-linked polyubiquitin chains (By similarity). Plays a role in signal transduction for cell growth and MYC induction mediated by IL-2 and GM-CSF. Potentiates BMP (bone morphogenetic protein) signaling by antagonizing the inhibitory action of SMAD6 and SMAD7. Has a key role in regulation of cell surface receptor-mediated endocytosis and ubiquitin-dependent sorting of receptors to lysosomes. Endosomal localization of STAMBP is required for efficient EGFR degradation but not for its internalization (By similarity). Involved in the negative regulation of PI3K-AKT-mTOR and RAS-MAP signaling pathways. Cytokine-mediated signal transduction in the JAK-STAT cascade requires the involvement of adaptor molecules. One such signal-transducing adaptor molecule contains an SH3 domain that is required for induction of MYC and cell growth. The protein encoded by this gene binds to the SH3 domain ...more
- ENST00000339566
- ENSP00000344742
- ENSG00000124356
- ENST00000394070
- ENSP00000377633
- ENST00000394073
- ENSP00000377636
- ENST00000409707
- ENSP00000386548
- AMSH
- AMSH
- MICCAP
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
kinase perturbation | 0.91 | ||
disease perturbation | 0.9 | ||
cell type or tissue | 0.84 | ||
virus perturbation | 0.79 | ||
histone modification site profile | 0.71 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 108.03 (req: < 5)
Gene RIFs: 31 (req: <= 3)
Antibodies: 277 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 108.03 (req: >= 5)
Gene RIFs: 31 (req: > 3)
Antibodies: 277 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 12
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 6
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0